Ser642

Site Information
GQISVQssEPssPEP SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 14161453

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 )
Disease tissue studied:	leukemia ( 2 ) , acute myelogenous leukemia ( 2 ) , lung cancer ( 1 ) , non-small cell lung cancer ( 1 )
Relevant cell line - cell type - tissue:	Calu 6 (pulmonary) ( 1 ) , H2077 (pulmonary) ( 1 ) , H322M (pulmonary) ( 1 ) , HCC2279 (pulmonary) ( 1 ) , Jurkat (T lymphocyte) ( 3 ) , KG-1 (myeloid) ( 2 ) , NCI-H1648 (pulmonary) ( 1 ) , NCI-H2172 (pulmonary) ( 1 )

References
1	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info
2	Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56 22115753 Curated Info
3	Mayya V, et al. (2009) Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal 2, ra46 19690332 Curated Info